CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy
- Citation:
- Blood vol 124 (21) abstr 543
- Meeting Instance:
- ASH 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3067
- Program:
- OGC
- Primary Committee:
- Transplant
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Ravi Vij
- Authors:
- Ravi Vij Vera Hars Thomas Shea Eva Hoke William Blum Richard Stone Mark Ratain Kouros Owzar Steven Devine
- Networks:
- Study
- CALGB-100801
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: